On the stock market since 2021, it operates in the world of health and science. It has 300 employees. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.72. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 34/100. For a turnaround signal, the stock first needs to close the gap with the market.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, CIRC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CIRC is a high-risk stock — not yet profitable, and its future rides on its product catching on.